Hairy Cell Leukemia

Data presented on Nipent shows its capability as a franchise compound

Published in Cancer Weekly, January 7th, 2003

SuperGen, Inc., (SUPG) announced that 12 abstracts and presentations on the company's anticancer drug, Nipent, validating the drug's capability as a franchise compound with the ability to treat a variety of hematological malignancies, were made at the 44th annual meeting of the American Society of Hematology, in Philadelphia.

Nipent is currently marketed by SuperGen for the treatment of hairy cell leukemia (HCL), a potentially fatal cancer of the blood and bone marrow that is characterized by a reduction in white blood cells, red blood cells, and platelets.

Highlights of Nipent-related clinical data presented at the ASH annual meeting:

A...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry